Columbia Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $826K | Sell |
4,189
-1
| -0% | -$193 | 0.16% | 93 |
|
|
2025
Q4 | $770K | Hold |
4,190
| – | – | 0.14% | 96 |
|
|
2025
Q3 | $643K | Hold |
4,190
| – | – | 0.12% | 109 |
|
|
2025
Q2 | $586K | Sell |
4,190
-53
| -1% | -$7.43K | 0.12% | 110 |
|
|
2025
Q1 | $624K | Hold |
4,243
| – | – | 0.12% | 118 |
|
|
2024
Q4 | $556K | Hold |
4,243
| – | – | 0.1% | 123 |
|
|
2024
Q3 | $661K | Sell |
4,243
-104
| -2% | -$16.8K | 0.12% | 109 |
|
|
2024
Q2 | $678K | Sell |
4,347
-200
| -4% | -$30.1K | 0.13% | 104 |
|
|
2024
Q1 | $612K | Hold |
4,547
| – | – | 0.12% | 107 |
|
|
2023
Q4 | $612K | Sell |
4,547
-204
| -4% | -$26.5K | 0.12% | 107 |
|
|
2023
Q3 | $643K | Sell |
4,751
-103
| -2% | -$14.1K | 0.14% | 104 |
|
|
2023
Q2 | $695K | Hold |
4,854
| – | – | 0.15% | 99 |
|
|
2023
Q1 | $674K | Hold |
4,854
| – | – | 0.15% | 97 |
|
|
2022
Q4 | $658K | Hold |
4,854
| – | – | 0.16% | 93 |
|
|
2022
Q3 | $532K | Buy |
4,854
+94
| +2% | +$11.9K | 0.14% | 99 |
|
|
2022
Q2 | $629K | Buy |
+4,760
| New | +$625K | 0.16% | 92 |
|
|
2021
Q4 | $643K | Sell |
5,516
-137
| -2% | -$16.1K | 0.13% | 104 |
|
|
2021
Q3 | $679K | Sell |
5,653
-101
| -2% | -$11.8K | 0.15% | 101 |
|
|
2021
Q2 | $689K | Sell |
5,754
-97
| -2% | -$10.6K | 0.15% | 100 |
|
|
2021
Q1 | $582K | Sell |
5,851
-86
| -1% | -$8.64K | 0.11% | 118 |
|
|
2020
Q4 | $594K | Hold |
5,937
| – | – | 0.12% | 115 |
|
|
2020
Q3 | $651K | Buy |
5,937
+88
| +2% | +$9.79K | 0.15% | 96 |
|
|
2020
Q2 | $619K | Sell |
5,849
-34
| -0.6% | -$3.51K | 0.15% | 97 |
|
|
2020
Q1 | $525K | Hold |
5,883
| – | – | 0.13% | 98 |
|
|
2019
Q4 | $5.87K | Sell |
5,883
-350
| -6% | -$33K | 0.14% | 112 |
|
|
2019
Q3 | $556K | Hold |
6,233
| – | – | 0.14% | 110 |
|
|
2019
Q2 | $515K | Sell |
6,233
-425
| -6% | -$33.3K | 0.14% | 117 |
|
|
2019
Q1 | $538K | Sell |
6,658
-358
| -5% | -$28.2K | 0.14% | 111 |
|
|
2018
Q4 | $533K | Sell |
7,016
-1,843
| -21% | -$144K | 0.16% | 102 |
|
|
2018
Q3 | $701K | Buy |
8,859
+207
| +2% | +$15.7K | 0.18% | 95 |
|
|
2018
Q2 | $608K | Hold |
8,652
| – | – | 0.18% | 103 |
|
|
2018
Q1 | $605K | Hold |
8,652
| – | – | 0.18% | 111 |
|
|
2017
Q4 | $600K | Sell |
8,652
-200
| -2% | -$13.5K | 0.17% | 112 |
|
|
2017
Q3 | $600K | Buy |
8,852
+3,150
| +55% | +$199K | 0.18% | 112 |
|
|
2017
Q2 | $388K | Buy |
5,702
+1,400
| +33% | +$91.4K | 0.13% | 134 |
|
|
2017
Q1 | $267K | Buy |
4,302
+1,025
| +31% | +$59.7K | 0.09% | 152 |
|
|
2016
Q4 | $179K | Sell |
3,277
-46
| -1% | -$2.61K | 0.06% | 175 |
|
|
2016
Q3 | $218K | Buy |
+3,323
| New | +$217K | 0.08% | 168 |
|
|
2016
Q2 | – | Sell |
-4,088
| Closed | -$230K | – | 178 |
|
|
2016
Q1 | $230K | Sell |
4,088
-250
| -6% | -$15K | 0.08% | 154 |
|
|
2015
Q4 | $294K | Hold |
4,338
| – | – | 0.12% | 136 |
|
|
2015
Q3 | $276K | Sell |
4,338
-72
| -2% | -$4.74K | 0.11% | 146 |
|
|
2015
Q2 | $280K | Buy |
4,410
+100
| +2% | +$6.85K | 0.11% | 157 |
|
|
2015
Q1 | $295K | Hold |
4,310
| – | – | 0.11% | 160 |
|
|
2014
Q4 | $303K | Hold |
4,310
| – | – | 0.12% | 150 |
|
|
2014
Q3 | $308K | Sell |
4,310
-600
| -12% | -$43.9K | 0.12% | 147 |
|
|
2014
Q2 | $365K | Sell |
4,910
-250
| -5% | -$18.1K | 0.15% | 139 |
|
|
2014
Q1 | $335K | Hold |
5,160
| – | – | 0.15% | 140 |
|
|
2013
Q4 | $306K | Buy |
+5,160
| New | +$280K | 0.14% | 135 |
|
Other funds holding AZN
IA
VCM
VAM
Columbia Asset Management's AZN Position: Q1 2026 in Review
Columbia Asset Management reduced its AstraZeneca (AZN) stake by 0.02% in Q1 2026, selling an estimated $193 and leaving 4,189 shares worth $826K. The position accounts for 0.16% of the portfolio, ranked #93.
Columbia Asset Management first reported a position in AZN in Q4 2013 and has held it in 48 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Columbia Asset Management held 4,189 shares of AstraZeneca worth $826K as of Q1 2026.
- Columbia Asset Management sold 1 AstraZeneca share in Q1 2026, an estimated $193.
- AstraZeneca made up 0.16% of Columbia Asset Management's portfolio in Q1 2026, its #93 holding.
- Columbia Asset Management first reported a position in AstraZeneca in Q4 2013 and has held it in 48 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Columbia Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.